Literature DB >> 28142309

Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.

Johannes Blom1, Sven Törnberg2.   

Abstract

Objective To evaluate interval cancers in the population-based colorectal cancer screening programme of Stockholm/Gotland, Sweden. Methods From 2008, individuals aged 60-69 were invited to colorectal cancer screening using biennial guaiac-based faecal occult blood test (Hemoccult®). Interval cancers, defined as colorectal cancer among participants not diagnosed by the screening programme but registered in the Swedish cancer register, were evaluated by cross-checking the screening histories for all cancers in the region 2008-2012. Results Of 203,848 individuals from nine different birth cohorts who participated (∼60%), 4530 (2.2%) tested positive. All invited individuals were followed up for 24 months after invitation. The cancer register reported 557 colorectal cancer, 219 (39.3%) screen-detected cancers and 338 (60.7%) interval cancers, generating both test- and episode sensitivities of approximately 40% and an interval cancer-rate of 17.1/10,000 tests. Among individuals with positive tests without colorectal cancer diagnosed at work-up colonoscopy, 37 interval cancers (10.9%) occurred. There was statistically significant lower sensitivity in women, ranging 22.4-32.2%, compared with 43.2-52.0% in men. Age-group and tumour location were not strongly correlated to screen-detected cancer rates. The programme sensitivity increased by year (20.3-25.0%), with successively more colorectal cancers diagnosed within the expanding programme (11.6-16.2%). Conclusion Interval cancer is a quality indicator of a screening programme. As the interval cancer-rate determined in a well-organized population-based screening programme was actually higher than the screen-detected cancer rate, a change to a more sensitive screening test is indicated. The lower screen-detected cancers among women, and compliance and quality of work-up colonoscopies also need attention.

Entities:  

Keywords:  Colorectal; faecal occult blood test; interval cancer; population; screening; sensitivity

Mesh:

Substances:

Year:  2017        PMID: 28142309     DOI: 10.1177/0969141316682983

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  3 in total

1.  Estimating Cancer Screening Sensitivity and Specificity Using Healthcare Utilization Data: Defining the Accuracy Assessment Interval.

Authors:  Jessica Chubak; Andrea N Burnett-Hartman; William E Barlow; Douglas A Corley; Jennifer M Croswell; Christine Neslund-Dudas; Anil Vachani; Michelle I Silver; Jasmin A Tiro; Aruna Kamineni
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-08-02       Impact factor: 4.090

2.  Faecal haemoglobin concentrations in women and men diagnosed with colorectal cancer in a national screening programme.

Authors:  Gavin Rc Clark; Jayne Digby; Callum G Fraser; Judith A Strachan; Robert Jc Steele
Journal:  J Med Screen       Date:  2021-11-22       Impact factor: 2.136

3.  Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.

Authors:  Hanna Ribbing Wilén; Deborah Saraste; Johannes Blom
Journal:  J Med Screen       Date:  2022-03-08       Impact factor: 1.687

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.